Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- EC Approves Add’l Indication of CHF for Ion Channel Inhibitor Ivabradine: Ono
February 17, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
- UMN Obtains Worldwide Rights for Norovirus and Rotavirus Combined Vaccine
February 16, 2012
- Pfizer Obtains Approval for Generics of 10 APIs
February 16, 2012
- Maruho Acquires Venture in Bid to Develop US Business Base
February 15, 2012
- Celecox Ranked Top Place in HP Market: RepTrack Survey
February 15, 2012
- MSD Issues Precaution for Gardasil on Syncope, Falls
February 15, 2012
- MSD Cautions against Syncope, Fall after Gardasil Vaccination
February 15, 2012
- Major Pharmacy Chains to Boost Efforts to Raise GE Dispensing Rates Despite Dissatisfaction with Revised Premiums
February 15, 2012
- Altheos Initiates PIIa Trial for ATS907 in the US: Asahi Kasei Pharma
February 14, 2012
- Sawai Wins Patent Lawsuit on Ebastine
February 14, 2012
- Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
- Otsuka HD Director Kimura Anticipates Seroquel Patent Expiry to Impact Abilify
February 14, 2012
- AnGes MG to Seek Return of ¥75 Million Patent Remuneration from Board Member Morishita
February 14, 2012
- Otsuka HD Files Application for Antituberculosis Drug Delamanid in Europe
February 13, 2012
- April-December Pharmaceutical Sales Up 4.1% Driven by Abilify: Otsuka HD
February 13, 2012
- Altheos Begins PIIa Trial for ATS907 in US: Asahi Kasei Pharma
February 13, 2012
- AnGes MG Announces Positive Results from Exploratory Trial of CIN Vaccine
February 13, 2012
- Nippon Kayaku to Make Largest-ever Investment in Pharma R&D, with Shift to Biosimilars
February 13, 2012
- Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…